325 related articles for article (PubMed ID: 33144586)
1. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
Fernando TM; Piskol R; Bainer R; Sokol ES; Trabucco SE; Zhang Q; Trinh H; Maund S; Kschonsak M; Chaudhuri S; Modrusan Z; Januario T; Yauch RL
Nat Commun; 2020 Nov; 11(1):5551. PubMed ID: 33144586
[TBL] [Abstract][Full Text] [Related]
2. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
3. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
4. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
[TBL] [Abstract][Full Text] [Related]
5. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
[TBL] [Abstract][Full Text] [Related]
6. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
7. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J; Ye X; Rousseau E; Januario T; Hamman BD; Rose CM; Cheung TK; Hinkle T; Soto L; Quinn C; Harbin A; Bortolon E; Chen X; Haskell R; Lin E; Yu SF; Del Rosario G; Chan E; Dunlap D; Koeppen H; Martin S; Merchant M; Grimmer M; Broccatelli F; Wang J; Pizzano J; Dragovich PS; Berlin M; Yauch RL
Nat Commun; 2022 Nov; 13(1):6814. PubMed ID: 36357397
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
Reichl KD; Lee ECY; Gopalsamy A
Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
[TBL] [Abstract][Full Text] [Related]
9. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
[TBL] [Abstract][Full Text] [Related]
10. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
11. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
[TBL] [Abstract][Full Text] [Related]
12. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
13. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.
Bellini A; Bessoltane-Bentahar N; Bhalshankar J; Clement N; Raynal V; Baulande S; Bernard V; Danzon A; Chicard M; Colmet-Daage L; Pierron G; Le Roux L; Planchon JM; Combaret V; Lapouble E; Corradini N; Thebaud E; Gambart M; Valteau-Couanet D; Michon J; Louis-Brennetot C; Janoueix-Lerosey I; Defachelles AS; Bourdeaut F; Delattre O; Schleiermacher G
Int J Cancer; 2019 Nov; 145(10):2781-2791. PubMed ID: 31018240
[TBL] [Abstract][Full Text] [Related]
14. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
15. SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
Tian Y; Xu L; Li X; Li H; Zhao M
Cancer Lett; 2023 Feb; 554():216022. PubMed ID: 36450331
[TBL] [Abstract][Full Text] [Related]
16. The Genomic Landscape of
Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
[TBL] [Abstract][Full Text] [Related]
17. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
[TBL] [Abstract][Full Text] [Related]
18. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
19. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
Guerrero-Martínez JA; Reyes JC
Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
[TBL] [Abstract][Full Text] [Related]
20. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
